Latest Content

Real-world CAPTIVATE study of 241 CAB LA users found no HIV acquisitions, 99% satisfaction and 97% preference over oral PrEP.

Researchers report positive results from open-label extension studies amid looming concerns that the long-acting injectable won’t be available where it is needed.

The lack of a standard, clear approach to present prices to consumers is a big reason why healthcare costs keep rising.

Disbursements for the HIV response dropped by 25% from 2024 to 2025

In the VOGUE trial, Dovato matched Biktarvy at week 48, demonstrating that it was noninferior in HIV-1 viral suppression in treatment-naïve adults, including high-risk patients.

Metformin, topiramate and three GLP-1 receptor agonists ranked as the most effective options for managing antipsychotic-induced weight gain, according to a new study published in JAMA Psychiatry.

The approval of centanafadine, now with the brand name, Simtriyo, introduces a new treatment approach for adults and children with ADHD.

Consumers are reshaping healthcare faster than the industry can adapt.

A once-weekly oral HIV treatment could make a major difference in resource-constrained settings, says the executive director of AVAC.

AVAC Executive Director Mitchell Warren says HIV prevention science has never been stronger, even as funding cuts have left program infrastructure badly weakened.

Renee Heffron, Ph.D., M.P.H., of the University of Alabama at Birmingham, says the HIV field has found new collaborations and funders after major disruptions in U.S. funding and cannot afford to lose ground on prevention.

Zambia has received just 13,000 of the tens of thousands of lenacapavir doses it hopes to get for PrEP, forcing rationing, says Lloyd Mulenga, M.B.Ch.B., Ph.D., a top health official in Zambia.

Zambia's Lloyd Mulenga, M.B.Ch.B., Ph.D., says U.S. funding cuts have imperiled HIV prevention programs in his country even as treatment and lab support continue.

Mulenga, a top health official in Zambia, says the country cut new HIV infections from 58,000 to 28,000 a year, but U.S. funding cuts and disruption threaten those gains, especially among young women.

A monthly pre-exposure prophylaxis (PrEP) pill would be less burdensome than daily pills and would be an important addition to the choices for HIV prevention, says Heffron, an HIV/AIDS researcher at the University of Alabama at Birmingham who is co-chairing a preconference meeting on HIV prevention today before the official start of the International AIDS Society meeting tomorrow in Rio de Janeiro, Brazil.

Renee Heffron, Ph.D., M.P.H., of the University of Alabama at Birmingham, discusses PrEP choice and alternative ways of delivery HIV prevention as she previews a preconference meeting, "HIV prevention, science and access" scheduled for today that she is co-chairing.

Semaglutide cut body weight by more than 24 lbs versus placebo in antipsychotic-treated patients with schizophrenia, according to a recent study published in JAMA Psychiatry.

Once-weekly zabopegdutide produced weight loss, better glycemic control, and favorable liver enzyme changes in a 67-patient phase 2 trial of patients with MASH.

Edward Machtinger, M.D., of UCSF says most mental illness and substance use trace back to trauma, and clinics that ignore this can retraumatize patients.

Industry leaders Tom Kraus and Shawn Gremminger debated 340B’s value during a Managed Healthcare Executive/Drug Topics webinar. Panelists clashed over transparency, safety-net eligibility, and how 340B savings should be spent.

Edward Machtinger, M.D., of UCSF says stigma often keeps women with HIV silent and isolated, discouraging care and disclosure to family and friends.

Adding thoracic radiotherapy to atezolizumab maintenance tripled serious side effects in small cell lung cancer without improving survival, a trial found.

A cost analysis of nearly 30,000 anti-VEGF visits found travel and missed work, not drug price, drive most of patients' out-of-pocket burden.

A survey by Spherix Global Insights also finds that health plans and pharmacy benefit managers are using Medicare’s Maximum Fair Prices as benchmarks when negotiating discounts for drugs that were not selected for price negotiations.

In this interview, Edward Machtinger, M.D., a professor of medicine at the University of California, San Francisco, director of the Center to Advance Trauma-Informed Healthcare and co-director of the Women's HIV Program, explains that many women with HIV actually die from issues like mental health problems, addiction, stigma, and violence rather than the virus itself, and he says we need better ways to capture these realities and provide more supportive, trauma-informed care.

Already approved for familial chylomicronemia syndrome, Redemplo now shows efficacy in severe hypertriglyceridemia; Arrowhead plans a U.S. sNDA filing before year-end.

Survey of PEPFAR-funded organizations shows the effects of the administration's policies.

An analysis at Montefiore Medical Center in New York finds that expanding CGM implementation in primary care improves diabetes outcomes and reduce acute care utilization, particularly in underserved populations.

Research suggests that uveitis could be a clinical marker for the cancer-targeted immune response that Keytruda and other immune checkpoint inhibitors are designed to produce.

In this discussion, Dolores Malaspina, M.D., a pharmacological sciences professor at the Icahn School of Medicine at Mount Sinai, explains how schizophrenia risk may be caused by trauma-alerted biological signaling, rather than genetics alone.

Despite similar diabetes technology use among the minority patients surveyed, Black patients showed higher A1C than White non-Hispanic patients, with insurance access and cost as the biggest barriers to using insulin pumps or connected insulin pens.